Search Result
Results for "
cholesterol absorption
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
6
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-45131
-
-
-
- HY-N0324F
-
|
Fluorescent Dye
|
Metabolic Disease
|
Cholic acid-Biotin is a biotin-labeled Cholic acid (HY-N0324). Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid has orally activity .
|
-
-
- HY-136059
-
|
Keap1-Nrf2
Autophagy
|
Cardiovascular Disease
Cancer
|
Desfluoro-ezetimibe is a desfluoro impurity of Ezetimibe. Ezetimibe is a potent, metabolically stable cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator .
|
-
-
- HY-101722
-
AC 223; DL-N-(α-Methylbenzyl)linoleamide
|
Acyltransferase
|
Metabolic Disease
|
Melinamide, an amide derivative of an unsaturated long-chain fatty acid, is an inhibitor of cholesterol absorption with an IC50 of 20.9 μM.
|
-
-
- HY-P2879A
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholesterol esterase, Porcine pancreas is an enzyme that hydrolyzes cholesterol ester to cholesterol and free fatty acid in the intestinal lumen. Cholesterol synthesized in the acinar cells and is stored in zymogen granules. Cholesterol esterase is also known as bile salt-stimulated lipase and carboxy ester lipasea, acts function for acceleration of cholesterol absorption.
|
-
-
- HY-107176A
-
HS-25
|
Others
|
Metabolic Disease
|
Hyzetimibe is a cholesterol absorption inhibitor. Hyzetimibe blocks the intestinal absorption of cholesterol and phytol. Hyzetimibe is well tolerated in animal models, with an LDmax 2000 mg/kg in rats and an LDmax 500 mg/kg in rhesus monkeys .
|
-
-
- HY-105086
-
CP148623
|
SARS-CoV
|
Infection
Metabolic Disease
|
Pamaqueside (CP148623) is a cholesterol absorption inhibitor and a potent binder of the SARS-CoV-2 receptor-binding domain (RBD), which may inhibit viral cellular entry. Pamaqueside can be utilized in metabolic and antiviral research .
|
-
-
- HY-19037
-
-
-
- HY-19497
-
AVE-5530; BART-1741
|
CETP
|
Metabolic Disease
|
Canosimibe is a cholesterol absorption inhibitor extracted from patent WO2004087655A1.
|
-
-
- HY-P2879C
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholesterol esterase, Schizophyllum commune is an enzyme that catalyzes the hydrolysis of cholesterol esters into free cholesterol and fatty acids, facilitating the absorption of cholesterol in the intestine.
Cholesterol esterase, Schizophyllum commune can be used in combination with cholesterol oxidase to measure cholesterol content .
|
-
-
- HY-P2879
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholesterol esterase, Pseudomonas is an enzyme that hydrolyzes cholesterol ester to cholesterol and free fatty acid in the intestinal lumen. Cholesterol synthesized in the acinar cells and is stored in zymogen granules. Cholesterol esterase is also known as bile salt-stimulated lipase and carboxy ester lipasea, acts function for acceleration of cholesterol absorption .
|
-
-
- HY-135391
-
Ezetimibe glucuronide; Ezetimibe β-D-glucuronide
|
Drug Metabolite
|
Metabolic Disease
|
Ezetimibe phenoxy glucuronide (Ezetimibe glucuronide) is the active metabolite of Ezetimibe. Antihyperlipoproteinemic activity . Ezetimibe is a potent cholesterol absorption inhibitor .
|
-
-
- HY-104081
-
Cholestyramine resin; Colestyramine
|
Others
|
Cardiovascular Disease
Cancer
|
Cholestyramine (Colestyramine) is a bile acid binding resin and can inhibit intestinal bile acid absorption which results in the increasing bile acid synthesis from cholesterol.
|
-
-
- HY-106902
-
|
Acyltransferase
|
Cardiovascular Disease
|
F-1394 is an orally active acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor that inhibits dietary cholesterol absorption in mice. F-1394 can be used in cardiovascular disease research .
|
-
-
- HY-134451
-
DEUP
|
Endogenous Metabolite
|
Metabolic Disease
|
Diethylumbelliferyl phosphate (DEUP), a selective and potent inhibitor of cholesterol esterase, does not inhibit protein kinase activity A in vitro, and it effectively disrupts steroidogenesis by blocking the transport of cholesterol into the mitochondria of steroidogenic cells, with an IC50 of 11.6 μM, potentially limiting dietary cholesterol absorption.
|
-
-
- HY-N0322B
-
|
Liposome
Endogenous Metabolite
|
Others
|
Cholesterol (Excipient, GMP Like) is the GMP Like class Cholesterol (HY-N0322), and can be used as pharmaceutical excipients. Cholesterol is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity.
In Vitro: Cholesterol (200 μg/mL; 40 h) increases the production of newly synthesized β-amyloid protein and enhances the secretion of Aβ1-40 in HEK cells transfected with APP .
In Vivo: Cholesterol (0.5% cholesterol in diet; oral; once daily; 7 days) increases plasma cholesterol in the hamster model, while the cholesterol absorption inhibitor SCH 48461 (10 mg/kg; oral gavage; once daily; 7 days) inhibits cholesterol absorption and reduces plasma cholesterol . Cholesterol (1% cholesterol + 0.5% bile acid in diet; oral; once daily; 7 days) increases plasma cholesterol levels in the male CD rat model, while SCH 48461 (2 mg/kg; oral; once daily; 7 days) reduces hepatic cholesterol ester accumulation . Cholesterol (0.25% cholesterol + 22% saturated fat diet; oral; once daily; 3 weeks) increases VLDL+LDL cholesterol levels in the rhesus monkey model, while SCH 48461 (0.2 mg/kg; oral; once daily; 3 weeks) maintains baseline levels and inhibits cholesterol absorption .
|
-
-
- HY-N0324A
-
Sodium cholate
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholic acid sodium is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid sodium is orally active .
|
-
-
- HY-N0324
-
Cholic acid
Maximum Cited Publications
14 Publications Verification
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .
|
-
-
- HY-16197
-
|
Acyltransferase
|
Inflammation/Immunology
|
Epicochlioquinone A can inhibit rat liver microsomal ACAT with IC50 of 1.7 μM, inhibit plasma lecithin cholesterol acyltransferase (LCAT) with IC50 of 15.8 μM, and inhibit cholesterol absorption in rats by 50% at 75 mg/kg .
|
-
-
- HY-N0324B
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholic acid sodium hydrate is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. Cholic acid sodium hydrate facilitates fat absorption and cholesterol excretion. Cholic acid sodium hydrate is orally active .
|
-
-
- HY-P2879B
-
|
Endogenous Metabolite
Biochemical Assay Reagents
|
Metabolic Disease
|
Cholesterol esterase, Candida cylindracea is an enzyme located in the intestines that hydrolyzes cholesterol esters into cholesterol and free fatty acids. Also known as bile salt-stimulated lipase or carboxylester lipase, this enzyme facilitates cholesterol metabolism and absorption in the body. It can also be used as a biochemical reagent, and is employed in conjunction with cholesterol oxidase (HY-P2848) to measure cholesterol levels .
|
-
-
- HY-106938
-
WAY-ACA 147
|
Acyltransferase
|
Cardiovascular Disease
Metabolic Disease
|
Eldacimibe is an ACAT2 inhibitor. Eldacimibe can lower plasma cholesterol levels by blocking cholesterol absorption and can prevent macrophages from turning into foam cells. Eldacimibe can be used in the study of cardiovascular diseases (atherosclerosis), endocrine and metabolic diseases (hypercholesterolemia) .
|
-
-
- HY-N0324S
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholic acid-d4 is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
|
-
-
- HY-N0324S1
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholic acid-d5 is the deuterium labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
|
-
-
- HY-N0324S2
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Cholic acid- 13C is the 13C-labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
|
-
-
- HY-101722R
-
AC 223 (Standard); DL-N-(α-Methylbenzyl)linoleamide (Standard)
|
Acyltransferase
Reference Standards
|
Metabolic Disease
|
Melinamide (Standard) is the analytical standard of Melinamide. This product is intended for research and analytical applications. Melinamide, an amide derivative of an unsaturated long-chain fatty acid, is an inhibitor of cholesterol absorption with an IC50 of 20.9 μM.
|
-
-
- HY-17376
-
-
-
- HY-135391S
-
Ezetimibe glucuronide-d4; Ezetimibe β-D-glucuronide-d4
|
Drug Metabolite
|
Metabolic Disease
|
Ezetimibe phenoxy glucuronide-d4 is the deuterium labeled Ezetimibe phenoxy glucuronide. Ezetimibe phenoxy glucuronide is the active metabolite of Ezetimibe. Antihyperlipoproteinemic activity . Ezetimibe is a potent cholesterol absorption inhibitor .
|
-
-
- HY-119220
-
JTT-130
|
Microsomal Triglyceride Transfer Protein (MTP)
|
Metabolic Disease
|
Granotapide (JTT-130) is an orally active microsomal triglyceride transfer protein (MTP) inhibitor. Granotapide reduces absorption of cholesterol and triglycerides through inhibition of MTP. Granotapide can be used for the research of dyslipidemia .
|
-
-
- HY-133971
-
5α,6α-Epoxycholesterol
|
Liposome
|
Others
|
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.
|
-
-
- HY-125854
-
|
Liposome
Cholinesterase (ChE)
Monoamine Oxidase
Apoptosis
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
Phosphatidylcholines, egg are a type of phosphatidylcholine that can be isolated and extracted from eggs, primarily present in egg yolks. As a major phospholipid component of cell membranes, Phosphatidylcholines, egg play a key role in providing nutrition and protection to the body. Phosphatidylcholines, egg can inhibit oxidative stress and neurotoxicity, exerting neuroprotective effects. Additionally, Phosphatidylcholines, egg can suppress the lymphatic absorption of cholesterol in the intestine and are also used in research on intestinal lipid absorption .
|
-
-
- HY-101397R
-
|
Reference Standards
Parasite
Drug Metabolite
Endogenous Metabolite
|
Infection
|
Cholic acid (Standard) is the analytical standard of Cholic acid. This product is intended for research and analytical applications. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .
|
-
-
- HY-N0324R
-
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
Cholic acid (Standard) is the analytical standard of Cholic acid. This product is intended for research and analytical applications. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid is orally active .
|
-
-
- HY-N0324AR
-
Sodium cholate (Standard)
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
Cholic acid (sodium) (Standard) is the analytical standard of Cholic acid (sodium). This product is intended for research and analytical applications. Cholic acid sodium is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid sodium is orally active[1][2].
|
-
-
- HY-120984
-
|
Endogenous Metabolite
|
Metabolic Disease
|
AcylCoA:cholesterol acyltransferase (ACAT) is an intracellular cholesteryl ester synthase tied closely to the absorption of dietary cholesterol.1 Oleic acid-2,6-diisopropylanilide is an inhibitor of acylCoA:cholesterol acyltransferase with an IC50 of 7 nM.2 When co-administered to rabbits or rats fed a high fat, high cholesterol diet, oleic acid-2,6-diisopropylanilide decreased low density lipoproteins and elevated high density lipoprotein levels when administered at 0.05%.
|
-
-
- HY-135388
-
ent-SCH 58235
|
Drug Metabolite
|
Cardiovascular Disease
|
ent-Ezetimibe (ent-SCH 58235) is the RRS-enantiomer of Ezetimibe. Ezetimibe is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator .
|
-
-
- HY-17376S1
-
SCH 58235-d4-1
|
Keap1-Nrf2
Autophagy
|
Cardiovascular Disease
Cancer
|
Ezetimibe-d4-1 is deuterium labeled Ezetimibe. Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
|
-
-
- HY-133114
-
EZM-K
|
Keap1-Nrf2
Autophagy
|
Cardiovascular Disease
Cancer
|
Ezetimibe ketone (EZM-K) is a phase-I metabolite of Ezetimibe. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator. Ezetimibe is a potent cholesterol absorption inhibitor .
|
-
-
- HY-17376R
-
SCH 58235 (Standard)
|
Reference Standards
Keap1-Nrf2
Autophagy
|
Cardiovascular Disease
Cancer
|
Ezetimibe (Standard) is the analytical standard of Ezetimibe. This product is intended for research and analytical applications. Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
|
-
-
- HY-17376S3
-
SCH 58235-13C6
|
Isotope-Labeled Compounds
Autophagy
Keap1-Nrf2
|
Cancer
|
Ezetimibe- 13C6 (SCH 58235- 13C6) is the 13C-labeled Ezetimibe (HY-17376). Ezetimibe (SCH 58235) is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
|
-
-
- HY-N0322BR
-
|
Reference Standards
Liposome
Endogenous Metabolite
|
Others
|
Cholesterol (Excipient) (Standard) is the analytical standard of Cholesterol (Excipient) (HY-N0322B). This product is intended for research and analytical applications. Cholesterol Excipient is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity. Cholesterol Excipient is a drug delivery carrier based on the lipid environment of the cell membrane. Due to its amphiphilicity, good biocompatibility and biodegradability, it can be used as an excipient in drug preparations. Cholesterol Excipient can self-assemble into delivery systems such as micelles, nanoparticles, and liposomes, and achieve controlled drug release by regulating membrane fluidity or responding to the microenvironment. It has the characteristics of high drug loading efficiency and good biocompatibility. Cholesterol Excipient is mainly used for research in the fields of targeted delivery of anticancer, antibacterial, antiviral drugs and treatment of skin diseases.
Cholesterol itself is also an endogenous regulator involved in the cleavage of amyloid precursor protein (APP) mediated by β-secretase and intestinal absorption, as well as an endogenous estrogen-related receptor α (ERRα) agonist. Cholesterol affects the subcellular localization of APP processing enzymes by regulating the cell membrane lipid environment, which can promote the production of β-amyloid protein and its adsorption and removal by probiotics. It is used to study the pathogenesis of Alzheimer's disease (AD) and the cholesterol-lowering function of probiotics[1][2][3][4][5].
|
-
Cat. No. |
Product Name |
Type |
-
- HY-N0324F
-
|
Dyes
|
Cholic acid-Biotin is a biotin-labeled Cholic acid (HY-N0324). Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion. Cholic acid has orally activity .
|
Cat. No. |
Product Name |
Type |
-
- HY-133971
-
5α,6α-Epoxycholesterol
|
Drug Delivery
|
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10342
-
|
Peptides
|
Cardiovascular Disease
|
Soystatin is a peptide extracted from soy protein, whose main activity is to inhibit the absorption of cholesterol. Soystatin, as a peptide with significant cholic acid binding ability, can be used in the study of cardiovascular diseases .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
Cat. No. |
Product Name |
|
Classification |
-
- HY-N0322B
-
|
|
Emulsifiers
Liposomal Film-forming Agents
|
Cholesterol (Excipient, GMP Like) is the GMP Like class Cholesterol (HY-N0322), and can be used as pharmaceutical excipients. Cholesterol is a component of the cell membrane and a precursor of some hormones, vitamin D and bile acid, with oral activity.
In Vitro: Cholesterol (200 μg/mL; 40 h) increases the production of newly synthesized β-amyloid protein and enhances the secretion of Aβ1-40 in HEK cells transfected with APP .
In Vivo: Cholesterol (0.5% cholesterol in diet; oral; once daily; 7 days) increases plasma cholesterol in the hamster model, while the cholesterol absorption inhibitor SCH 48461 (10 mg/kg; oral gavage; once daily; 7 days) inhibits cholesterol absorption and reduces plasma cholesterol . Cholesterol (1% cholesterol + 0.5% bile acid in diet; oral; once daily; 7 days) increases plasma cholesterol levels in the male CD rat model, while SCH 48461 (2 mg/kg; oral; once daily; 7 days) reduces hepatic cholesterol ester accumulation . Cholesterol (0.25% cholesterol + 22% saturated fat diet; oral; once daily; 3 weeks) increases VLDL+LDL cholesterol levels in the rhesus monkey model, while SCH 48461 (0.2 mg/kg; oral; once daily; 3 weeks) maintains baseline levels and inhibits cholesterol absorption .
|
-
- HY-133971
-
5α,6α-Epoxycholesterol
|
|
Cholesterol
|
Cholesterol-5α,6α-epoxide is an epoxide derivative of cholesterol formed by the enzymatic oxidation of cholesterol in the liver and other tissues. Cholesterol-5α,6α-epoxide has unique chemical properties that make it an important intermediate in the biosynthesis of bile acids, which play a key role in the digestion and absorption of dietary fats. It also has a potential physiological role in regulating cholesterol metabolism and transport, although its biological function is not fully understood.
|
-
- HY-125854
-
|
|
Phospholipids
|
Phosphatidylcholines, egg are a type of phosphatidylcholine that can be isolated and extracted from eggs, primarily present in egg yolks. As a major phospholipid component of cell membranes, Phosphatidylcholines, egg play a key role in providing nutrition and protection to the body. Phosphatidylcholines, egg can inhibit oxidative stress and neurotoxicity, exerting neuroprotective effects. Additionally, Phosphatidylcholines, egg can suppress the lymphatic absorption of cholesterol in the intestine and are also used in research on intestinal lipid absorption .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: